An interventional study of Hyperglycemia Minimization Algorithm in Type 1 Diabetes, Hypoglycemia and Hyperglycemia, sponsored by Jaeb Center for Health Research. Completed at 2 sites in United States. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 21st largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2016, is one of 10 with no phase, and was the 25th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2002; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 29 interventional studies, 77 across the 7 observational. Of the 34 that completed or were terminated, 20 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
1 of the studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06959316Jaeb Center for Health ResearchT1D Pregnancy & Me | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective: to gain experience in children and younger adolescents with in-home use of an algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is projected overnight and to obtain feasibility, safety, and initial efficacy data
Study Design: randomized controlled trial, with randomization on a night level within subject Patient Population: Youth 6.0 - \<15 years old with type 1 diabetes treated with daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months who have HbA1c \< 10.0%.
Sample Size: 30 subjects
Study Duration and Visit Schedule: duration approximately 3 months, with preliminary run-in activities followed by up to 90 days spent in clinical trial phase of study; clinic visits at enrollment, following CGM and system assessment run-in phases, at start of clinical trial phase, at 21-day point of clinical trial phase, and after 42 nights of successful system use
Major Efficacy Outcomes:
Major Safety Outcomes: CGM measures of hypo- and hyperglycemia, including morning blood glucose and mean overnight sensor glucose; adverse events including severe hypoglycemia and diabetic ketoacidosis
Subjects who are eligible for the clinical trial initially will use a Veo insulin pump and Enlite CGM sensor at home for a minimum of 6 days/week over a 2-week period to verify that the subject is able to use the CGM and insert sensors.
The first 10 subjects enrolled will be 11 to \<15 years of age and will participate in an Algorithm Assessment Phase of approximately 10 nights of system use each with PLGS and Hyper Minimization active. Results of the approximate 100 nights will be reviewed with the study DSMB to assess safety and determine whether any adjustments to the algorithm parameters are needed. If adjustments are needed, the Algorithm Assessment Phase will be repeated with the same age restriction, using the same 10 subjects if possible. If no adjustments are needed and the DSMB judges it safe to continue the study, enrollment will continue across the full 6 to \<15 age range.
Subjects who enroll in the study after the completion of the Algorithm Assessment Phase will use the closed-loop system at home for 5 nights of system use each with PLGS and Hyper Minimization active to demonstrate their ability to use the system and submit study data to the Coordinating Center.
Subjects who successfully demonstrate their ability to use the system at home as described above will be eligible for the randomized trial phase. This phase consists of use of the full system in the home for approximately 42 nights:
A randomization schedule on the laptop will be used to determine whether the system will run in PLGS+Hyper Minimization mode or PLGS-only.
Once approximately 200 nights of randomized clinical trial phase data are available, the study DSMB will perform another data review to determine whether it is safe to continue the study. Subjects already using the study system at home will continue to use it during the DSMB review process, but no additional subjects will begin home use of the system until the DSMB review is complete.
Upon completion of the study, subjects as well as study clinicians will be asked to complete a human factors usability questionnaire regarding use of the study system.
There will be a follow-up (optional) extension phase for subjects who exhibit safe and competent use of the system at home. They may be given the option to continue home use of the system for up to 56 days to assess whether data-driven, subject-level customization of algorithm parameters improves glycemic outcomes compared with generic algorithm parameters that are identical for each subject.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
\< 10.0%
Exclusion Criteria:
Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Device: Hyperglycemia Minimization Algorithm
The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Percent Time 70-<180mg/dL Per Night Over 42 Nights
A single percentage calculated for each subject by pooling all CGM readings from the PLSG+HM nights and PLGS-only nights for the same subject. All CGM readings regardless of the amount of data will be weighted equally in the pooled percentage regardless of how they distribute across nights.
Time frame: 42 nights
Mean Overnight Sensor Glucose
Time frame: Up to 42 nights
Glucose Standard Deviation and Coefficient of Variation
Time frame: Up to 42 nights
Percent of Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 Nights
Time frame: 42 nights
Percent Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 Nights
Time frame: 42 nights
Percent Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 Nights
Time frame: 42 nights
Percent Time >180 mg/dl (10.0 mmol/L) Per Night Over 42 Nights
Time frame: 42 nights
| Milestone | All Participants |
|---|---|
| Started | 35 |
| Completed 23 nights with plgs+hyper minimization mode | 28 |
| Completed 23 nights plgs only | 28 |
| Completed | 28 |
| Not completed | 7 |
| Withdrew: Hba1c screening failure | 1 |
| Withdrew: Schedule conflict | 4 |
| Withdrew: Sensor performance | 2 |
A single percentage calculated for each subject by pooling all CGM readings from the PLSG+HM nights and PLGS-only nights for the same subject. All CGM readings regardless of the amount of data will be weighted equally in the pooled percentage regardless of how they distribute across nights.
| percentage of time | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 76 ± 9 |
| PLGS-only mode | 66 ± 11 |
| mg/dL | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 147 ± 13 |
| PLGS-only mode | 160 ± 15 |
| mg/dL | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 46 (41 to 55) |
| PLGS-only mode | 55 (48 to 63) |
| percentage of time | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 0.2 (0.0 to 0.3) |
| PLGS-only mode | 0.1 (0.0 to 0.4) |
| percentage of time | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 0.6 (0.2 to 1.1) |
| PLGS-only mode | 0.7 (0.2 to 0.9) |
| percentage of time | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 1.8 (1.0 to 2.9) |
| PLGS-only mode | 1.8 (0.9 to 2.6) |
| percentage of time | All Participants |
|---|---|
| PLGS+Hyper Minimization mode | 21 (15 to 30) |
| PLGS-only mode | 30 (22 to 40) |
Collected over 42 nights. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
35 participants enrolled, 7 withdrew prior to randomization; HbA1c screen failure, N=1, scheduling conflict, N=4, sensor performance, N=2
| Age, Customized(years) | All Participants |
|---|---|
| Median | 12 (6 to 14) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 15 |
| Male | 13 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| White Non-Hispanic | 22 |
| Hispanic | 2 |
| Pacific Islander | 1 |
| Asian | 1 |
| Black | 1 |
| More than one race | 1 |
| Diabetes Duration(years) | All Participants |
|---|---|
| Median | 4 (3 to 7) |
| Body-Mass Index(kg/m^2") | All Participants |
|---|---|
| Median | 17.8 (16.6 to 19.8) |
| HbA1c(percent) | All Participants |
|---|---|
| Median | 7.9 (7.2 to 8.8) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Mar 2017, 10 months.
Results were first posted in Oct 2026, 9 years 7 months after primary completion.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 10 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →